Other

University of Texas System

Karl Folkers Foundation for Biomedical and Clinical Research

Per H Langsjoen

Karl A Folkers

Peter H Langsjoen

Richard A Willis

Disclosed are methods for inhibiting the side effects attendant treatment with HMG-CoA reductase inhibitors. Treatment of a patient with and HMG-CoA reductase inhibitor in combination with coenzyme Q.sub.10 provides a reduction in patient cholesterol levels and guards against typical HMG-CoA reductase-inhibitor side effects, most notably liver dysfunction and cardiac dysfunction. The combination of lovastatin, an HMG-CoA reductase inhibitor, and coenzyme Q.sub.10 in ratios of between 1:2 to 1:29 provide significant enhancement of a patient's caridac condition. By way of example, other HMG-CoA reductase inhibitors which may be included in the claimed combinations include pravastatin, compactin, fluvastatin, dalvastatin, simvastatin, BMY 22089, GR-95030, HR-780, CI-981, SQ 33,600, and BMY 22566 and XU-62-320.

Use of coenzyme Q.sub.10 in combination with HMG-CoA reductase inhibitor

The present invention comprises the serious side effect of mevinolin to depress body levels of coenzyme Q.sub.10 and to correspondingly depress cardiac function and the circumvention of this side effect by the clinical administration of a formulation of coenzyme Q.sub.10 concommitantly with the administration of the mevinolin.

Amelioration of reductions of coenzyme Q.sub.10 in cardiomyopathy

Therapy with a pharmaceutical formulation of coenzyme Q.sub.10 (CoQ.sub.10) of patients with Acquired Immune Deficiency Syndrome, known by the acronym AIDS and of patients with other retroviral diseases including the AIDS-related complex known as ARC is useful to reduce or negate opportunistic infections, adenopathy and other undesirable clinical symptoms. CoQ.sub.10 therapy may be used in conjunction with antibiotic therapy to prevent or suppress secondary opportunistic infections.

Growing community of inventors

Temple, TX, United States of America

Per H Langsjoen